Determining the IC50 values of 30 legacy ACVR1/ALK2 inhibitors
| Main Authors: | Wong, Jong Fu, Bullock, Alex |
|---|---|
| Format: | info dataset Journal |
| Terbitan: |
, 2018
|
| Subjects: | |
| Online Access: |
https://zenodo.org/record/1308265 |
Daftar Isi:
- A large number of ACVR1/ALK2 inhibitors were previously synthesised by Paul Brenner’s team (Target Discovery Center, University of Oxford) for the purpose of treating Fibrodysplasia Ossificans Progressiva (FOP). Although these compounds were not designed with blood-brain-barrier permeability in mind, they can serve as good bench-marks for my cellular assays. Therefore, 30 of these legacy compounds were chosen to be tested before other new bespoke Diffused Intrinsic Pontine Glioma (DIPG) compounds from Ontario Institute for Cancer Research (OICR) and Charles River Laboratories (CRL).